An isomerization feature-based method for purifying and preparing punicalagin is provided, wherein pomegranate peel extract is used as a raw material. The isomerization feature-based method avoids impurities contained in the punicalagin based on structural characteristics, for example, the punicalagin in the pomegranate peel extract has two mutually convertible isomers. In the isomerization feature-based method, a pilot-scale preparative liquid chromatography is used to obtain a large amount of the punicalagin having a purity higher than 98% from a complex pomegranate peel extract. The isomerization feature-based method is simple, an obtained punicalagin has high purities and a preparation is in a massive scale. The isomerization feature-based has a strong reference value for purification and preparation of compounds with isomerization features.

An isomerization feature-based method for purifying and preparing punicalagin is provided, wherein pomegranate peel extract is used as a raw material. The isomerization feature-based method avoids impurities contained in the punicalagin based on structural characteristics, for example, the punicalagin in the pomegranate peel extract has two mutually convertible isomers. In the isomerization feature-based method, a pilot-scale preparative liquid chromatography is used to obtain a large amount of the punicalagin having a purity higher than 98% from a complex pomegranate peel extract. The isomerization feature-based method is simple, an obtained punicalagin has high purities and a preparation is in a massive scale. The isomerization feature-based has a strong reference value for purification and preparation of compounds with isomerization features.

The present disclosure relates to derivatives of neamine-based aminoglycoside antibacterial drugs modified in position C6′, C2′ and/or C5″. The modifications impart favorable properties regarding activity against ESKAPE pathogens, evasion of resistance traits and increased selectivity, enabling systemic use of the compounds.

The present disclosure relates to derivatives of neamine-based aminoglycoside antibacterial drugs modified in position C6′, C2′ and/or C5″. The modifications impart favorable properties regarding activity against ESKAPE pathogens, evasion of resistance traits and increased selectivity, enabling systemic use of the compounds.

Reagents, methods, and kits for assaying enzymes associated with lysosomal storage diseases MPS-I, MPS-II, MPS-IIIA, MPS-IIIB, MPS-IVA, MPS-VI, and MPS VII.

Reagents, methods, and kits for assaying enzymes associated with lysosomal storage diseases MPS-I, MPS-II, MPS-IIIA, MPS-IIIB, MPS-IVA, MPS-VI, and MPS VII.

Reagents, methods, and kits for assaying enzymes associated with lysosomal storage diseases MPS-I, MPS-II, MPS-IIIA, MPS-IIIB, MPS-IVA, MPS-VI, and MPS VII.

Reagents, methods, and kits for assaying enzymes associated with lysosomal storage diseases MPS-I, MPS-II, MPS-IIIA, MPS-IIIB, MPS-IVA, MPS-VI, and MPS VII.

Disclosed herein is a novel and inventive synthesis of amino-deoxyavermectins, and in particular, the economically significant, anthelminthic macrolide eprinomectin. The synthesis proceeds via reductive amination of an intermediate in which the allylic alcohol of the benzofuran ring is deprotected. Advantageously, the method of the present invention obviates the need for chromatographic purification.

Disclosed herein is a novel and inventive synthesis of amino-deoxyavermectins, and in particular, the economically significant, anthelminthic macrolide eprinomectin. The synthesis proceeds via reductive amination of an intermediate in which the allylic alcohol of the benzofuran ring is deprotected. Advantageously, the method of the present invention obviates the need for chromatographic purification.